Sweden's national proton therapy clinic — clinical research partner for particle therapy, radiation dosimetry, and cancer patient radiation risk studies.
Skandionkliniken is Sweden's national proton therapy centre — a purpose-built clinical facility in Uppsala operated as a joint municipal authority by Sweden's regional councils. Their core work is delivering proton beam therapy to cancer patients, particularly those with brain tumours and lymphomas where precision dose delivery is critical. In EU research, they contribute direct clinical expertise: real patient cohorts, treatment data, dosimetry know-how, and patient selection databases that pure research institutes cannot offer. They serve as the bridge between particle physics infrastructure and clinical oncology practice, making them a rare asset in research consortia that need a working proton therapy site rather than a laboratory setting.
INSPIRE (2018–2022) positioned Skandionkliniken as a clinical partner in Europe's proton therapy research infrastructure, contributing patient treatment experience, dosimetry protocols, and mathematical modelling of dose delivery.
INSPIRE explicitly lists patient selection databases as a keyword, reflecting Skandionkliniken's role in defining which cancer patients benefit most from proton over conventional radiotherapy.
SINFONIA (2020–2024) targets low-dose radiation risk in lymphoma and brain tumour patients, where Skandionkliniken provides clinical cases and follow-up data to quantify long-term radiological harm from therapeutic and diagnostic exposures.
INSPIRE's radiobiology keyword signals that Skandionkliniken participates in translating laboratory radiation biology findings into clinical proton therapy practice.
Skandionkliniken entered EU research in 2018 through INSPIRE, focused squarely on building proton therapy as a clinical and research infrastructure — transnational access, joint research activities, radiobiology, and the operational mechanics of running a particle therapy centre. By 2020, with SINFONIA, the emphasis shifted upstream toward radiation risk: what happens to patients at lower doses, across a broader disease spectrum including lymphoma. This suggests the clinic has moved from establishing its clinical identity to asking harder safety questions about radiation exposure in cancer management. The trajectory points toward becoming a reference site for radiation epidemiology, not just a treatment provider.
Skandionkliniken is evolving from a clinical treatment site into a data-rich research partner for radiation safety and long-term patient outcome studies, making them increasingly relevant to epidemiology and radiation protection consortia.
Skandionkliniken has exclusively participated as a consortium partner — never as coordinator — across both projects, suggesting they prefer contributing clinical data and expertise rather than managing research programmes. With 31 unique partners across 15 countries from just two projects, they operate within large, internationally distributed consortia typical of EU research infrastructure networks. This profile indicates they are sought after as a specialist node that provides something others cannot replicate: a functioning national proton therapy facility with real patient throughput.
Skandionkliniken has built connections with 31 distinct consortium partners spanning 15 countries across just two projects, reflecting the broad European reach of particle therapy and radiation medicine research networks. Their partners are concentrated in EU research infrastructure circles, likely including major proton therapy centres, university hospitals, and radiation physics institutes across Western and Northern Europe.
Skandionkliniken is one of very few nationally mandated proton therapy centres in Europe that actively participates in EU-funded research — most proton therapy sites are either purely clinical or purely academic. As a public body treating real patients under Sweden's healthcare system, they bring regulatory-grade clinical data, long-term follow-up records, and patient access that private or university-based partners cannot easily replicate. For consortia building around particle therapy, radiation safety, or oncology outcomes, Skandionkliniken offers what no research institute alone can: a live clinical environment at national scale.
